CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

NCT06371157 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT469

EST. COMPLETION2025-10-25

Conditions

Hepatocellular Carcinoma

Interventions

AK104LenvatinibTACEPlacebo for AK104Placebo for Lenvatinib

Study details

SPONSORAkeso

START DATE2024-08-02

Related company profiles

Akeso

9926.HK

Primary source

ClinicalTrials.gov record NCT06371157 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06371157
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record